Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RBN-2397 |
Synonyms | |
Therapy Description |
RBN-2397 is a small molecule inhibitor that targets PARP7, potentially inducing type I interferon signaling, which may lead to an immune response and tumor regression (PMID: 34375612). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RBN-2397 | RBN2397|Atamparib | RBN-2397 is a small molecule inhibitor that targets PARP7, potentially inducing type I interferon signaling, which may lead to an immune response and tumor regression (PMID: 34375612). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04053673 | Phase I | RBN-2397 | RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study | Unknown status | USA | ESP | 0 |